PMID- 36866344
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230304
IS  - 2223-8956 (Electronic)
IS  - 1016-3190 (Print)
IS  - 1016-3190 (Linking)
VI  - 35
IP  - 1
DP  - 2023 Jan-Mar
TI  - Comparative study of different combinations of mirabegron and antimuscarinics in 
      treatment for overactive bladder syndrome in elderly patients.
PG  - 62-68
LID - 10.4103/tcmj.tcmj_209_21 [doi]
AB  - OBJECTIVES: To compare the therapeutic efficacy, adverse events (AEs), and 
      patient preference in elderly patients with overactive bladder (OAB) receiving 
      different combinations of mirabegron and solifenacin. MATERIALS AND METHODS: 
      Elderly OAB patients received mirabegron 25 mg (M25) daily for 1 month (1M) 
      followed by randomization to receive M25 (Group 1), mirabegron 50 mg (M50, Group 
      2), solifenacin 5 mg (S5, group 3); or M25 plus S5 (Group 4) for further 2 
      months. Efficacy and AEs were evaluated. At the end of 3M, patients' preferred 
      option for future treatment was investigated. RESULTS: A total of 168 patients 
      were enrolled, and 100 completed 3-month treatment. At 1M, all parameters 
      improved significantly except postvoid residual (PVR), 23 (13.7%) patients had no 
      symptom, 16 (9.5%) had no improvement, and 10 (6.0%) withdrew from the trial. 
      Compared parameters at 3M with 1M revealed that quality of life, Patient's 
      Perception of Bladder Condition scores, and voided volume improved significantly 
      in group 1; the OAB Symptom Score (OABSS) increased in group 2; mean PVR and 
      Global Response Assessment (GRA) deteriorated in group 3; and the OABSS and GRA 
      improved in group 4. At 3M, the AEs prevalence increased significantly in group 
      3. Only 38.1% in group 4 preferred long-term usage of combination therapy. 
      CONCLUSION: M25 daily is effective and safe in treating elderly OAB patients. 
      Dose escalation to 50 mg or shifting to S5 does not increase the therapeutic 
      efficacy. Combining M25 with S5 provides better treatment efficacy but is 
      associated with lower patient compliance than M25 alone.
CI  - Copyright: (c) 2021 Tzu Chi Medical Journal.
FAU - Kuo, Yuh-Chen
AU  - Kuo YC
AD  - Department of Urology, Yangming Branch of Taipei City Hospital, Taipei, Taiwan.
AD  - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, and Tzu Chi University, Hualien, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, and Tzu Chi University, Hualien, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20211210
PL  - India
TA  - Tzu Chi Med J
JT  - Tzu chi medical journal
JID - 101770275
PMC - PMC9972936
OTO - NOTNLM
OT  - Antimuscarinics
OT  - Beta-3-adrenoceptor agonist
OT  - Overactive bladder syndrome
OT  - Treatment
COIS- Dr. Hann-Chorng Kuo, an editorial board member at Tzu Chi Medical Journal, had no 
      role in the peer review process of or decision to publish this article. The other 
      author declared no conflict of interest in writing this paper.
EDAT- 2021/12/10 00:00
MHDA- 2021/12/10 00:01
PMCR- 2021/12/10
CRDT- 2023/03/03 02:44
PHST- 2021/07/16 00:00 [received]
PHST- 2021/08/04 00:00 [revised]
PHST- 2021/10/18 00:00 [accepted]
PHST- 2023/03/03 02:44 [entrez]
PHST- 2021/12/10 00:00 [pubmed]
PHST- 2021/12/10 00:01 [medline]
PHST- 2021/12/10 00:00 [pmc-release]
AID - TCMJ-35-62 [pii]
AID - 10.4103/tcmj.tcmj_209_21 [doi]
PST - epublish
SO  - Tzu Chi Med J. 2021 Dec 10;35(1):62-68. doi: 10.4103/tcmj.tcmj_209_21. 
      eCollection 2023 Jan-Mar.